BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao Z, Zhang D, Wu F, Tu J, Song J, Xu M, Ji J. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. J Cell Mol Med 2021;25:549-60. [PMID: 33210432 DOI: 10.1111/jcmm.16108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhou Y, Zhang Y, Bao J, Chen J, Song W. Low Temperature Plasma Suppresses Lung Cancer Cells Growth via VEGF/VEGFR2/RAS/ERK Axis. Molecules 2022;27:5934. [DOI: 10.3390/molecules27185934] [Reference Citation Analysis]
2 Sun D, Liu J, Wang Y, Dong J. Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. Front Oncol 2022;12:944537. [DOI: 10.3389/fonc.2022.944537] [Reference Citation Analysis]
3 Huang S, Ma Z, Zhou Q, Wang A, Gong Y, Li Z, Wang S, Yan Q, Wang D, Hou B, Zhang C. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma. Int J Biol Sci 2022;18:4357-71. [PMID: 35864956 DOI: 10.7150/ijbs.69969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xu Z, Xu J, Sun S, Lin W, Li Y, Lu Q, Li F, Yang Z, Lu Y, Liu W. Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma. Redox Biology 2022. [DOI: 10.1016/j.redox.2022.102351] [Reference Citation Analysis]
5 Tang Q, Liu Y, Peng X, Wang B, Luan F, Zeng N. Research Progress in the Pharmacological Activities, Toxicities, and Pharmacokinetics of Sophoridine and Its Derivatives. Drug Des Devel Ther 2022;16:191-212. [PMID: 35082485 DOI: 10.2147/DDDT.S339555] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yan Y, Qiu Y, Davgadorj C, Zheng C. Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection. Front Cell Infect Microbiol 2022;12:847539. [DOI: 10.3389/fcimb.2022.847539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Guo J, Zhu P, Ye Z, Wang M, Yang H, Huang S, Shu Y, Zhang W, Zhou H, Li Q. YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS. Front Pharmacol 2021;12:744578. [PMID: 34658879 DOI: 10.3389/fphar.2021.744578] [Reference Citation Analysis]
8 Wang Q, Li Y, Li KW, Zhou CZ. Sophoridine: A review of its pharmacology, pharmacokinetics and toxicity. Phytomedicine 2021;:153756. [PMID: 34615616 DOI: 10.1016/j.phymed.2021.153756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Lu L, Hu J, Li G, An T. Low concentration Tetrabromobisphenol A (TBBPA) elevating overall metabolism by inducing activation of the Ras signaling pathway. J Hazard Mater 2021;416:125797. [PMID: 33878653 DOI: 10.1016/j.jhazmat.2021.125797] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
10 Zhao Z, Zhang D, Wu F, Tu J, Song J, Xu M, Ji J. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. J Cell Mol Med 2021;25:549-60. [PMID: 33210432 DOI: 10.1111/jcmm.16108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]